Who owns Protagonist Therapeutics, Inc?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of PTGX from SEC Form 13F filings across 344 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 344 institutions disclosed 75.8M shares of Protagonist Therapeutics, Inc worth $9.29B — about 115% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
344
13F holders
$9.29B
value, 2026 filers
115%
of shares outstanding (75.8M sh)
71
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of PTGX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.3M | $1.26B | 0.0% | 15.6% | +5.4% |
| 2 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 6.3M | $778.2M | 3.6% | 9.6% | 0.0% |
| 3 | RTW INVESTMENTS, LP | 5.1M | $620.4M | 5.3% | 7.7% | 0.0% |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLCNEW | 3.6M | $444.9M | 0.0% | 5.5% | new |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 3.4M | $418.8M | 0.1% | 5.2% | -5.1% |
| 6 | UBS Group AG | 3.4M | $416.7M | 0.1% | 5.2% | -34.4% |
| 7 | STATE STREET CORP | 3.3M | $407.2M | 0.0% | 5% | +6.6% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLCNEW | 2.9M | $349.8M | 0.0% | 4.3% | new |
| 9 | JOHNSON & JOHNSON | 2.4M | $300.2M | 37.6% | 3.7% | 0.0% |
| 10 | Invesco Ltd. | 2.3M | $286.9M | 0.0% | 3.5% | +8.1% |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.1M | $263.5M | 0.0% | 3.3% | +29.1% |
| 12 | Jupiter Topco LLCNEW | 2.1M | $261.0M | 0.1% | 3.2% | new |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1.7M | $213.5M | 0.0% | 2.6% | +4.3% |
| 14 | Woodline Partners LP | 1.4M | $173.3M | 0.5% | 2.1% | 0.0% |
| 15 | BANK OF AMERICA CORP /DE/ | 1.3M | $162.4M | 0.0% | 2% | +2.2% |
| 16 | JENNISON ASSOCIATES LLC | 1.2M | $141.2M | 0.1% | 1.7% | +7.4% |
| 17 | PERCEPTIVE ADVISORS LLC | 981,879 | $120.4M | 1.8% | 1.5% | -20.2% |
| 18 | ADAR1 Capital Management, LLC | 960,863 | $117.8M | 5.4% | 1.5% | -3.3% |
| 19 | MORGAN STANLEY | 905,992 | $111.1M | 0.0% | 1.4% | -11.0% |
| 20 | Alyeska Investment Group, L.P. | 889,298 | $109.0M | 0.3% | 1.3% | +49.9% |
| 21 | Hood River Capital Management LLC | 882,738 | $108.2M | 0.8% | 1.3% | +6.4% |
| 22 | GOLDMAN SACHS GROUP INC | 812,852 | $99.6M | 0.0% | 1.2% | +4.4% |
| 23 | Driehaus Capital Management LLC | 731,053 | $89.6M | 0.5% | 1.1% | +1.4% |
| 24 | Clearbridge Investments, LLC | 725,335 | $88.9M | 0.1% | 1.1% | +16.6% |
| 25 | FMR LLC | 672,186 | $82.4M | 0.0% | 1% | +1.5% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.